Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2024-12-17 Capital/Financing Update
Country IN India
Listing BSE.NS BROOKS

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is an official announcement dated December 17, 2024, regarding the outcome of a Fund Raising Committee meeting. It details the approval of a preferential issue of equity shares, including the number of shares, issue price, and proposed allottees. It also mentions the approval of the notice for an Extraordinary General Meeting (EGM) to obtain shareholder approval for the preferential issue. The document includes regulatory references to SEBI (Listing Obligations and Disclosure Requirements) Regulations and SEBI ICDR Regulations, indicating compliance with capital raising rules. The content focuses on fundraising activities and capital structure changes rather than financial results or management commentary. The document is not a full financial report but an update on capital raising and related approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (5805 characters) and detailed content support this classification with high confidence.
2024-12-17 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is an official announcement dated December 11, 2024, from Brooks Laboratories Limited regarding the outcome of a Board Meeting. The key content includes approval of a fund raise of up to Rs. 75 crores through issuance of equity shares on a preferential basis, subject to shareholder approval and regulatory compliance. It also announces the formation of a Fund Raising Committee to oversee the process. The document references SEBI regulations and states that further disclosures will be made after finalization. The document is relatively short (3410 characters) and serves as an update on financing activities rather than a full financial report or detailed presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-12-11 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2024-12-07 English
Board Meeting — Fund Raising
Board/Management Information Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve a proposal for raising funds through issuance of equity shares, approval of an Extraordinary General Meeting (EGM) notice, appointment of a scrutinizer, and recording certificates from auditors. It is an intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to board meeting announcements. The document does not contain financial statements or detailed financial data but is an announcement of an upcoming board meeting and related agenda items. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or financial statement itself.
2024-12-07 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement addressed to stock exchanges (BSE and NSE) regarding the publication of financial results. It references the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulations 30 and 47, which pertain to disclosure of financial results. The text mentions extracts of newspaper publications of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024. The document includes detailed financial data and analysis, not just a brief announcement or a link to a report. The length is substantial (15,000 characters), indicating it is not a mere announcement but contains substantive financial information. The content aligns with an Interim / Quarterly Report (IR) as it covers quarterly and half-year financial results with actual financial data and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-11-11 English
Financial Result Updates
Regulatory Filings
2024-11-09 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.